etanidazole and Adenocarcinoma, Basal Cell
etanidazole has been researched along with Adenocarcinoma, Basal Cell in 14 studies
Etanidazole: A nitroimidazole that sensitizes hypoxic tumor cells that are normally resistant to radiation therapy.
etanidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitro-1H-imidazol-1-yl)acetic acid with the amino group of ethanolamine. Used as a radiosensitising agent for hypoxic tumour cells.
Research Excerpts
Excerpt | Relevance | Reference |
---|---|---|
" Changes in tumor hypoxia were assessed by comparing the binding of two hypoxia tracers, pimonidazole and EF5 given before and after Atrasentan administration." | 7.75 | Atrasentan (ABT-627) enhances perfusion and reduces hypoxia in a human tumor xenograft model. ( Cho, H; Koutcher, JA; Li, XF; Ling, CC; Lupu, ME; Russell, J; Yang, KM, 2009) |
"RTOG Protocol 90-20 was designed to evaluate the effect of the hypoxic cell sensitizer Etanidazole (SR-2508) on locally advanced adenocarcinoma of the prostate treated with concurrent external beam irradiation." | 5.08 | Results of a phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer (RTOG Protocol 90-20). ( Buzydlowski, JW; Coleman, CN; DelRowe, JD; Forman, JD; Lawton, CA; Marcial, VA; Rotman, M, 1996) |
"Fifty eight previously untreated patients with locally advanced adenocarcinoma of the prostate were entered on a Phase II trial of etanidazole (ETA) combined with standard external beam radiation therapy." | 5.07 | Phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer. ( Beard, C; Buswell, L; Coleman, CN; Johnson, D; Noll, L; Rose, MA, 1994) |
" Changes in tumor hypoxia were assessed by comparing the binding of two hypoxia tracers, pimonidazole and EF5 given before and after Atrasentan administration." | 3.75 | Atrasentan (ABT-627) enhances perfusion and reduces hypoxia in a human tumor xenograft model. ( Cho, H; Koutcher, JA; Li, XF; Ling, CC; Lupu, ME; Russell, J; Yang, KM, 2009) |
" The secondary goal was to prospectively evaluate the utility of pharmacokinetic monitoring and dose-modification of the incidence and severity of the dose-limiting peripheral neurotoxicity." | 2.67 | The efficacy of pharmacokinetic monitoring and dose modification of etanidazole on the incidence of neurotoxicity: results from a phase II trial of etanidazole and radiation therapy in locally advanced prostate cancer. ( Buswell, L; Coleman, CN; Noll, L; Riese, N; Rose, MA, 1992) |
"Pimonidazole was given 1h preheating, EF5 at various times during or after treatment, 1h later the animals were sacrificed." | 1.35 | Changes in tumor hypoxia induced by mild temperature hyperthermia as assessed by dual-tracer immunohistochemistry. ( Humm, JL; Li, GC; Li, XF; Ling, CC; Russell, J; Sun, X; Urano, M; Xing, L, 2008) |
Research
Studies (14)
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 2 (14.29) | 18.7374 |
1990's | 9 (64.29) | 18.2507 |
2000's | 2 (14.29) | 29.6817 |
2010's | 1 (7.14) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors
Authors | Studies |
---|---|
Ali, R | 1 |
Apte, S | 1 |
Vilalta, M | 1 |
Subbarayan, M | 1 |
Miao, Z | 1 |
Chin, FT | 1 |
Graves, EE | 1 |
Sun, X | 1 |
Li, XF | 2 |
Russell, J | 2 |
Xing, L | 1 |
Urano, M | 1 |
Li, GC | 1 |
Humm, JL | 1 |
Ling, CC | 2 |
Yang, KM | 1 |
Lupu, ME | 1 |
Cho, H | 1 |
Koutcher, JA | 1 |
Tamulevicius, P | 1 |
Streffer, C | 1 |
Blanke, G | 1 |
Luscher, G | 1 |
Beard, C | 2 |
Buswell, L | 4 |
Rose, MA | 2 |
Noll, L | 2 |
Johnson, D | 1 |
Coleman, CN | 4 |
Watkins-Bruner, D | 1 |
Scott, C | 1 |
Lawton, C | 1 |
DelRowe, J | 1 |
Rotman, M | 2 |
Cella, D | 1 |
Bornstein, BA | 1 |
Zouranjian, PS | 1 |
Hansen, JL | 1 |
Fraser, SM | 1 |
Gelwan, LA | 1 |
Teicher, BA | 2 |
Svensson, GK | 1 |
Recht, A | 1 |
Clark, J | 1 |
Ravikumar, T | 1 |
Busse, PM | 1 |
O'Dwyer, PJ | 1 |
Panting, L | 1 |
LaCreta, FP | 1 |
Clapper, ML | 1 |
Holden, SA | 1 |
Goff, DA | 1 |
Wright, JE | 1 |
Tretyakov, O | 1 |
Ayash, LJ | 1 |
Lawton, CA | 1 |
Buzydlowski, JW | 1 |
Forman, JD | 1 |
Marcial, VA | 1 |
DelRowe, JD | 1 |
Riese, N | 1 |
Taghian, A | 1 |
Lespinasse, F | 1 |
Guichard, ME | 1 |
Newman, HF | 1 |
Bleehen, NM | 1 |
Workman, P | 1 |
Clinical Trials (1)
Trial Overview
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Intraoperative Intraperitoneal Chemoperfusion to Treat Peritoneal Minimal Residual Disease in Stage III Ovarian Cancer: A Randomized Phase II Trial[NCT02567253] | Phase 2 | 56 participants (Actual) | Interventional | 2016-03-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
Trials
5 trials available for etanidazole and Adenocarcinoma, Basal Cell
Article | Year |
---|---|
Phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer.
Topics: Adenocarcinoma; Etanidazole; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms | 1994 |
RTOG's first quality of life study--RTOG 90-20: a phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer.
Topics: Adenocarcinoma; Aged; Data Collection; Etanidazole; Feasibility Studies; Follow-Up Studies; Humans; | 1995 |
Combined-modality therapy of esophageal cancer with radiotherapy, etanidazole, and cisplatin-fluorouracil, with or without surgery: neurotoxicity, other toxicities and outcome.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cel | 1994 |
Results of a phase II trial of external beam radiation with etanidazole (SR 2508) for the treatment of locally advanced prostate cancer (RTOG Protocol 90-20).
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Etanidazole; Humans; Male; Middle Aged; Neoplasm Staging; P | 1996 |
The efficacy of pharmacokinetic monitoring and dose modification of etanidazole on the incidence of neurotoxicity: results from a phase II trial of etanidazole and radiation therapy in locally advanced prostate cancer.
Topics: Adenocarcinoma; Combined Modality Therapy; Drug Evaluation; Etanidazole; Humans; Male; Nitroimidazol | 1992 |
Other Studies
9 other studies available for etanidazole and Adenocarcinoma, Basal Cell
Article | Year |
---|---|
18F-EF5 PET Is Predictive of Response to Fractionated Radiotherapy in Preclinical Tumor Models.
Topics: Adenocarcinoma; Animals; Carcinoma; Cell Hypoxia; Cell Line, Tumor; Dose Fractionation, Radiation; E | 2015 |
Changes in tumor hypoxia induced by mild temperature hyperthermia as assessed by dual-tracer immunohistochemistry.
Topics: Adenocarcinoma; Analysis of Variance; Animals; Cell Hypoxia; Colorectal Neoplasms; Etanidazole; Fema | 2008 |
Atrasentan (ABT-627) enhances perfusion and reduces hypoxia in a human tumor xenograft model.
Topics: Adenocarcinoma; Animals; Atrasentan; Colonic Neoplasms; Combined Modality Therapy; Etanidazole; Gado | 2009 |
The effects of radiosensitizers on intermediary metabolism in vivo.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adenocarcinoma; Animals; Dihydroxyacetone Phosphate; Etanidazo | 1984 |
Local hyperthermia, radiation therapy, and chemotherapy in patients with local-regional recurrence of breast carcinoma.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Breast Neopl | 1993 |
SR2508 (etanidazole) pharmacokinetics and biochemical effects in tumor and normal tissues of scid mice bearing HT-29 human colon adenocarcinoma.
Topics: Adenocarcinoma; Animals; Cell Line; Colonic Neoplasms; Etanidazole; Glutathione; Glutathione Transfe | 1993 |
Antitumor efficacy and pharmacokinetic analysis of 4-hydroperoxycyclophosphamide in comparison with cyclophosphamide +/- hepatic enzyme effectors.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Pro | 1996 |
Radiosensitization by the combination of etanidazole (SR-2508) and pimonidazole (Ro 03-8799) in human tumor xenografts.
Topics: Adenocarcinoma; Animals; Cell Survival; Drug Synergism; Etanidazole; Female; Humans; Melanoma; Mice; | 1991 |
A phase I study of the combined hypoxic cell radiosensitizers, Ro 03-8799 and SR 2508: a preliminary report of single-dose toxicity, pharmacokinetics and tumour concentrations.
Topics: Adenocarcinoma; Drug Combinations; Drug Evaluation; Etanidazole; Humans; Melanoma; Nitroimidazoles; | 1986 |